Eagle Health Investments LP raised its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 213.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 179,322 shares of the company’s stock after purchasing an additional 122,022 shares during the quarter. Protagonist Therapeutics makes up about 3.3% of Eagle Health Investments LP’s investment portfolio, making the stock its 12th largest position. Eagle Health Investments LP’s holdings in Protagonist Therapeutics were worth $18,901,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. NEXTBio Capital Management LP bought a new position in shares of Protagonist Therapeutics in the fourth quarter valued at about $20,055,000. Jennison Associates LLC bought a new stake in Protagonist Therapeutics during the 4th quarter worth about $28,924,000. Clearbridge Investments LLC bought a new stake in Protagonist Therapeutics during the 4th quarter worth about $42,783,000. Keystone Investors PTE Ltd. acquired a new stake in Protagonist Therapeutics in the 4th quarter valued at about $2,305,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its position in Protagonist Therapeutics by 26.3% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 114,036 shares of the company’s stock valued at $9,960,000 after acquiring an additional 23,719 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.
Insider Activity at Protagonist Therapeutics
In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at $922,880.50. The trade was a 53.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 161,130 shares of company stock worth $16,355,220 over the last ninety days. Company insiders own 5.19% of the company’s stock.
Protagonist Therapeutics Trading Down 0.4%
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. The company had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. Research analysts forecast that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current year.
Wall Street Analysts Forecast Growth
PTGX has been the subject of a number of research analyst reports. Barclays boosted their target price on shares of Protagonist Therapeutics from $119.00 to $151.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group reissued a “neutral” rating and issued a $110.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective for the company. Citizens Jmp boosted their price objective on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Zacks Research raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $123.00.
Get Our Latest Analysis on Protagonist Therapeutics
Protagonist Therapeutics Profile
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
